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Increased intestinal hydration by activation of the epithelial enzyme linked receptor guany-
late cyclase C (GC-C) is a pharmacological principle for treating constipation. Activating
mutations in the GUCY2C gene encoding GC-C cause Familial GUCY2C diarrhea syn-
drome (FGDS) which has been diagnosed with severe dysmotility.
Aim
To investigate gut motility and hormones before and after a meal in FGDS patients and com-
pare with healthy controls (HC).
Subjects and methods
Bristol stool chart and stool frequency was assessed. Before and after a meal occlusive and
non-occlusive contractions were obtained using ultrasound. A wireless motility capsule
(WMC) recorded gut transit time, pH, contractions and pressure. Plasma levels of selected
gut hormones were measured at different time points.
Results
The FGDS patients had 4 (range 1–10) loose stools/day and prolonged total gut transit time
compared to HC, 55.5 h vs 28.5 h, respectively,with significantly increased colon transit
time. In FGDS patients, pH in duodenum, small bowel and colon was increased and the
number of contractions and the intraluminal pressure were significantly decreased, mea-
sured by WMC. Ultrasound showed in small bowel increased number of non-occlusive con-
tractions in the FGDS patients. Serotonin (5-HT) plasma levels in the HC peaked 30 min
after the meal, while the FGDS patients had no response.
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Conclusion
Despite having diarrhea, the FGDS patients have prolonged transit time through the gut
compared to HC, particularly in colon. The reduced number of intestinal contractions and
lack of 5-HT release after a meal in FGDS patients surprisingly resemble colonic motility dis-
turbances seen in patients with constipation.
Introduction
The guanylate cyclase C receptor (GC-C) in humans is expressed on the epithelial cells from
duodenum to rectum [1], and the receptor is activated by the endogen ligands guanylin (GN)
and uroguanylin (UGN), and the heat stable ST toxin from E.Coli as well as the drug linaclo-
tide used in the therapy of irritable bowel syndrome with constipation (IBS-C) [2,3]. The
GC-C pathway is important for controlling the systemic fluid and electrolyte homeostasis [1].
Activation of GC-C leads to increased secretion of chloride, sodium and water to the intestinal
lumen [4]. Apart from intestinal hydration, GC-C signalling influences the intestinal barrier
function and epithelial differentiation, proliferation and tumorigenesis. A role in regulation of
satiety and lipolysis has also been suggested [5–8].
In 2012 Fiskerstrand et al described an activating mutation of GUCY2C encoding for GC-C
leading to the Familial GUCY2C diarrhea syndrome (FGDS) in 32 members of a Norwegian
family [2]. The clinical characteristics of this rare, autosomal dominant inherited disease are
diarrhea, intestinal inflammation (25% have Crohn’s disease (CD)) and symptoms resembling
IBS with diarrhea (IBS-D), but without severe abdominal pain. Thirty percent of the family
members had surgery due to small bowel obstruction, which in some was due to volvulus and
pseudo-obstruction [2]. Chronic activated GC-C signalling in FGDS patients leads to elevated
intracellular cyclic guanosine monophosphate (cGMP) leading to phosphorylation of the cys-
tic fibrosis transmembrane regulator (CFTR) resulting in increased secretion of Cl-, bicarbon-
ate and fluid into the intestinal lumen. GC-C activation also leads to an inhibition of the Na+/
H+-exchanger followed by reduced absorption of Na+[9].This leads to increased efflux of fluid
into the intestinal lumen explaining the diarrhea seen in these patients. In a recent study, we
used ultrasound to examine the fluid distribution and motility, and found that the FGDS
patients had severe dysmotility in the intestine, particularly in the small bowel [10]. However,
very little is known about how a chronic activated GC-C signalling is affecting the human
intestine, and in this study we aimed to elucidate this.
Wireless motility capsule (WMC, SmartPill Corporation, Given Imaging, Yokneam, Israel)
and ultrasound are two different methods to study the intestinal motility. The WMC can be
used to measure total gut transit time, regional gut transit time through the stomach, small
bowel and colon, as well as temperature, pH, contractions per min and intraluminal pressure
through the whole gut. WMC recordings are comparable with established motility testing
modalities and is mainly used to diagnose gastric emptying, particularly in patients with dia-
betic gastroparesis [11]. Furthermore, it is also suggested in the diagnosis of constipation and
various motility disorders of the gut [11,12]. Ultrasound is a non-invasive tool for bowel exam-
ination, gives us the possibility to examine the intestinal contractility pattern in real time, and
can be used to observe aspects of contractility which are not detected by methods relying on
pressure differences only [13–17].
Dysmotility in the intestine is defined as an inadequate (incoordinated or excessive
response) in the intestinal muscular activity [18], of exogenous or endogen origin, e.g.
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myopathic or neuropathics disorders [19]. Motility disorders may manifest differently, and
both IBS-C and IBS-D have been proposed to involve motility disturbances.
Several gastrointestinal (GI)- hormones have been shown to influence hydration and GI
motility such as GN, UGN and serotonin (5-HT), and the ileal brake regulating hormones glu-
cagon-like peptide-1 (GLP-1) and the pancreatic peptide YY (PYY). The “ileal brake” is medi-
ated neuronally by sympatho-adrenergic and vagal pathways and hormonally by gut peptides
(GLP-1, PYY and neurotensin) exerting an inhibitory reflex affecting the transit time of lumi-
nal content through the gut [20]. Gut hormones are mainly stored in the enteroendocrine cells
(EEC) which are found scattered throughout the intestine [21]. EEC cells act as sensors for
intestinal luminal content (e.g.nutrients and bacterial products) enabling a cross-talk between
the endocrine cells, immune cells, neurological and muscular system. Therefore, they are con-
sidered important for the regulation of intestinal motility [21].
In this study, we combined WMC and ultrasound with blood samples of motility regulating
hormones, and hypothesized that FGDS patients have changed transit time, intraluminal pres-
sure and pH in the gut, as well as changes in circulating levels of gut hormones.
Subjects and methods
Study participants
This is an explorative case control study. The controls were matched for age and gender. The
majority of the FGDS patients live in western part of Norway, and 24 adults (> 18 years) were
invited to participate in this study.
The HCs were recruited using bulletin boards at Haukeland University Hospital and via a
website for subject recruitment.
The participants of the HC group were interviewed before inclusion and had no previous
history of gastrointestinal disease. Body mass index (BMI) and blood samples (haemoglobin
(Hb), c-reactive protein (CRP), creatinine, electrolytes, aspartate and alanine aminotransfer-
ases (AST and ALT) and glutamyltranspeptidase (GGT) were obtained.None of the HC ful-
filled the Rome III criteria for IBS. Exclusion criteria were history of bowel surgery (except
appendectomy) or gastrointestinal complaints or symptoms resembling IBS. None of the par-
ticipants were allowed to use antidepressants or medications which could affect motility.
Preparation prior to the examination
Three days prior to the examination all participants had to avoid food rich on tryptophan such
as nuts, chocolate, ice, large meals with beef or seafood. Alcohol or caffeine-containing prod-
ucts were prohibited 24 hours before the study and they had to refrain from alcohol as long as
the capsule was in the gut. Samples from all participants were obtained after an overnight fast
of>8 hours. All participants met in a fasting state on the examination day.
Bristol stool chart (BSC) was assessed in all participants, and shows seven categories of stool
type where 1–2 indicate constipation, 3–4 normal and 5–7 indicate diarrhea[22] Only in the
FGDS group additional information about stool frequency for the last 3 months and 24 hours
was obtained. As the patients have symptoms resembling IBS-D, but without severe pain, we
used the Irritable Bowel Symptom Score (IBS-SSS) in order to obtain the severity of their com-
plaints [23].
Informed consent was obtained from all participants and the study was approved by the
Regional Committee for Medical Research Ethics, Haukeland University Hospital (Registra-
tion number 2014/2222) and performed in accordance with the Declaration of Helsinki.
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Meal
A standardized meal called SmartBar (SmartPill Corporation, Given Imaging, Yokneam,
Israel) was used in the study. It contains 260 kCal (fat 2 g, sodium 300 mg, carbohydrate 50 g,
fiber 2 g, protein13 g), and was given 10 minutes prior to ingestion of the WMC.
Wireless motility capsule (WMC)
The WMC system (SmartPill Corporation, Given Imaging, Yokneam, Israel) consists of an
ingestible single-use capsule, a receiver and display software. The capsule measures 26 mm ×
13 mm and has sensors that measure pH, temperature and pressure. The pH measurement is
accurate to ± 0.5 pH units and pressure measurement is accurate to ± 5 mmHg below 100
mmHg. The gastric emptying time (GET) is defined as time between capsule ingestion and
entry to pyloric passage (abrupt and sustained rise in pH (> 2 units)). Small Bowel transit time
(SBTT) is defined as the time between passage into the small bowel and to a drop in pH of
approximately 1 unit indicating the arrival of the capsule in the cecum [24]. Colon transit time
(CTT) is the time from cecum until body exit (BE) when s a major drop in temperature is
seen.Small bowel and colon transit time (SBCTT) and the whole gut transit time (WGTT) are
recorded. According to the software specification,pressure and pH in duodenum are defined
as the first 30 min after gastric emptying.
The test started with the ingestion of a SmartBar after an overnight fast. After 10 min the
patients swallowed the WMC with 120 ml of water. After intake of the capsule the participants
were not allowed to eat the following 6 hours, but could drink up to 100 ml water.
Ultrasound
The ultrasound examination was conducted with a Logic E9 ultrasound scanner (GE Health-
care, Milwaukee, USA), using a convex probe C1-5 (2.8–5.0 MHz) for abdominal overview
and a linear probe 9L (8.4–9.0 MHz) for detailed bowel examination at baseline (before intake
of the meal). All ultrasound measurements were performed with patients lying in a prone posi-
tion. The following procedures were repeated 30, 60, 120 and 240 min after intake of the meal.
Occlusive and non-occlusive contractions were counted and defined as in our previous
study [10] where an occlusive contraction was defined as an active indentation of the bowel
wall occluding the lumen, and a non-occlusive contraction as an active indentation in which
luminal content can be observed between the anterior and dorsal wall during a contraction.
We obtained one minute video recordings from the jejunum in the upper left quadrant and of
the ileum in the lower right quadrant. If the lumen was not fluid-filled, we were not able to dif-
ferentiate between occlusive and non-occlusive contractions, and the measurements were
excluded.
The number of fluid-filled small bowel loops was counted using a magnetic navigation sys-
tem as shown in our previous study [10] where we used a commercially available magnetome-
ter-based position and orientation measurement (POM) device on the ultrasound scanner
which enabled tracking of the scan head in the magnetic field.
Presence of small bowel segments with turbulent intraluminal and back and forth flow of
content and non-occlusive contractions with no propulsive movements were defined as
“snowglobe” phenomenon [10], and noted as present or not in left upper quadrant and lower
right quadrant, respectively.
The antrum was localized on a sagittal section in front of the superior mesenteric vein and
the abdominal aorta. The image was frozen, and the area measured by tracing the circumfer-
ence following the outer edge of the hypoechoic proper muscle layer using the built-in caliper
of the scanner. In order to study if there were differences in the mesenteric flow in fasting
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subjects and in response to the meal, we examined the resistive index (RI) of the superior
mesenteric artery (SMA). This reflects the circulatory resistance in the small bowel and proxi-
mal large bowel[25] It was sampled with the SMA oriented in long axis in the sagittal plane 2
cm distal to its origin to avoid turbulence. The angle between the ultrasound beam and the
SMA was kept smaller than 60˚. The RI was calculated according to the formula: peak-systolic
velocity minus end-diastolic velocity divided by the peak-systolic velocity.
Blood samples
Gastrointestinal hormones (ProUGN, ProGN, 5-HT, PYY and GLP-1) were measured before
(baseline) and after the meal (30, 60, 120 and 240 min). Electrolytes, CRP, creatinine, and elec-
trolytes were measured at baseline. The blood was taken from a peripheral vein using 18G can-
nula, extension line and a three ways stop cock. The system was flushed with 2 ml sterile saline
after extraction.
Plasma for ProGN, ProUGN and PYY determination was obtained from EDTA blood by
centrifugation at 1800 x g for 10 min at 4˚C. Trasylol™ (Bayer Pharmaceuticals) was added to
the blood samples for PYY analyses immediately after blood collection to give a final concen-
tration of 500 KIU/mL Trasylol™. Plasma for GLP-1 determination was obtained by adding
10 μL DPP-IV inhibitor (Dipeptidyl peptidase IV, DPP4-010, DRG Diagnostics, Germany) per
mL EDTA blood prior to sampling, and centrifuged at 1000 x g for 10 min at 4˚C. The blood
samples were put on ice immediately after sampling and centrifuged within 20 min. The
plasma was then aliquoted and stored at -80˚C until analysis.
Concentration of 5-HT was measured in platelet poor plasma (PPP). To prepare PPP, 3 mL
mL EDTA blood was centrifuged at 200 x g for 10 min at room temperature within 5 min
from sampling to give platelet rich plasma (PRP). Furthermore, 400 μL of the upper two-thirds
of the PRP was immediately transferred to another tube and centrifuged at 4500 x g for 10 min
at 4˚C to give PPP. The PPP was aliquoted and stored at -80˚C until analyzed for 5-HT.
Hormone analyzes
The plasma concentrations of the gastrointestinal hormones were determined by commercial
enzyme linked immunisorbent assays (ELISA) kits. ProGN and ProUGN were analyzed with
kits from BioVendor, Karasek, Czech Republic (catalog number RD191069200R and RD19
1046100R, respectively). GLP-1 and 5-HT were determined with kits from IBL International,
Hamburg, Germany (catalog number RE53121 and RE59121, respectively) and total PYY was
determined using a kit from EMD Millipore Corporation, Billerica, MA, USA (catalog number
EZHPYYT66K). The ELISAs were performed according to the manufacturer’s instructions.
The optical density from each ELISA was measured by SPECTRAmax microplate reader
(Molecular Devices, Sunnyvale, CA, US) and concentrations of each specimen were calculated
by the SoftMaxPro Software version 5.4.5.000 (Molecular Devices, Sunnyvale, CA, US) using
an algorithm for the best standard curve fitting.
Statistics
Data are shown as median and range. Differences between groups were measured using the
unpaired t-test or Mann-Whitney U-test. Pearson or Spearman was used for analyses of corre-
lation. The non-parametric methods were used when variables were not considered to have a
normal distribution. P-value < 0.05 was considered significant. Interobserver agreement was
assessed for all 38 WMC examinations and was analyzed by two different observers (HLvV
and DAS). Limits of agreement using the difference between observations versus mean values
of the two observations were calculated according to Bland and Altman [26]. Data were
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analysed with SPSS 22.0 Software (Chicago, Illinois, USA), figures were made with both SPSS
and Graph Pad Prism version 5.02 for Windows (Graph Pad Software Inc., La Jolla, CA, USA).
Results
Twenty-one FGDS patients between 21 and 77 years, (median 49 years), 10 females and 11
males, and 24 healthy controls (HC) between 21 and 76 years,(40 years), 14 females and 10
males, participated in this study.
Clinical characteristics of gastrointestinal functions
The majority of the participating FGDS patients had loose stools on daily basis(n = 20) and
prior to the FGDS diagnosis they were suspected of having IBS-D. Seventeen patients reported
having loose stools from childhood. Six patients had undergone abdominal surgery, and 5
patients had been diagnosed with CD. Only one FGDS patient reported no abdominal
discomfort.
The median number /24 hours of stools for FGDS patients were 4 (range 1–10) and 4 (1–6)
during the last 3 months. 80% of the FGDS patients had watery or liquid stool with BSC 7 (4–
7), wheras all the healthy controls had normal stool concistency 4 (3–4). Therefore, the num-
ber of stools per day were not recorded in the HC The median IBS-SSSwas only obtained in
the FGDS patients, and was 132 (30–335) which corresponds to scores observed in patients
with mild IBS [27]. All the HCs had normal clinical examination and blood samples. BMI in
FGDS was 24 (19–29) and in HC 24 (19–30) respectively.
Gut transittime and pH
Two FGDS patients refused the WMC examination, and in one patient the recordings were
incomplete due to failure of the device. Four of the FGDS patients had contraindications for
the examination due to previous multiple bowel resections and symptoms of intermittens par-
tial/pending bowel obstruction. One HC had incomplete signals from the colon due to device
failure, and the pH, pressure and transit time in colon were excluded from the analysis. Finally,
24 HC and 14 FGDS patients were examined with WMC.
The transit time for the whole gut and colon was significantly longer in the FGDS patients
than in the HC (p< 0.01)(Table 1). In six of the FGDS patients, the expected pH drop when
the capsule reached the cecum was not observed, and the transition was determined by observ-
ing changes in the variability of the pressure waves and pH (Fig 1). There was also a trend
towards longer transit time through the small bowel in the FGDS patients 6 h (2.3–47.4) com-
pared to the healthy group,4.2 h (2.6–6.6.), (p = 0.07).
The results of the interobserver analyses from all gut segments in FGDS and HC are dis-
played in S1 Table. The small bowel comparison is displayed in Fig 2 as correlation plots and
Bland & Altman plots.
There were no significant differences in the pH between FGDS and HC in the stomach and
antrum (p = 0.85, p = 0.78), but the pH was significantly elevated in duodenum (p = 0.009), in
small bowel (p = 0.007) and colon (p = 0.001) in FGDS patients compared to HC (Fig 3).
Intraluminal pressure and intestinal contractions
Intraluminal pressure measured by WMC was significantly lower in FGDS patients compared
to HC in duodenum (p = 0.01), and in small bowel (p = 0.02) and in colon (p = 0.002), whereas
in antrum and stomach there was no significant differences (p = 0.41, p = 0.33) (Table 2).
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Correspondingly, there were significantly less contractions per min registered by WMC in
duodenum (p = 0.03), small bowel (p = 0.001) and colon (p = 0.02) respectively in the FGDS
patients compared with the HC, whereas in antrum and stomach there were no differences
(p = 0.45, 0.46), Fig 4.
Using ultrasound, significantly more non-occlusive contractions in the ileum were
observed in the FGDS patients compared to HC at all measured points in time (Fig 5), but no
differences in the number of occlusive contractions between the two groups at any time point.
Table 1. Transit time. Transit parameters in hours, (median and range) for Gastric Emptying (GET), Small Bowel (SBTT), Colon (CTT), Small Bowel and
Colon (SBCTT) and Whole Gut Transit Time (WGTT) for Healthy Controls and FGDS patients.
Healthy controls FGDS patients
Segments Median (h) Range Median (h) Range p-value
GET 3.0 0.6–5.2 3.1 2.0–5.7 0.4
SBTT 4.2 2.6–6.6 6.0 2.3–47.4 0.07
CTT 21.5 3.1–64.6 39.5 20.9–137.4 <0.01
SBCTT 25.6 6.6–70.1 50.8 26.1–141.3 <0.01
WGTT 28.5 9.3–73.6 55.4 27.6–143.4 <0.01
https://doi.org/10.1371/journal.pone.0185496.t001
Fig 1. A summary of WMC (wireless motility capsule) data. The blue line represents the temperature, the
green the pH and the red peaks the pressure along the entire gut. The green vertical lines display the
ileocoecal transition zone. In 1A (Healthy Control) the pH drop is more than 1 unit, in 1B (FGDS) the
characteristic pH drop in the ileocoecal junction is not present. This was found in 6 FGDS patients.
https://doi.org/10.1371/journal.pone.0185496.g001
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The jejunal non-occlusive contractions were significantly more in the FGDS patients at time
points 60 and 240 min after the meal, Fig 5.
Intestinal fluid content
The total number of fluid-filled small bowel loops was significantly increased at all measured
points in time (p< 0.001) in FGDS patients compared to the HC (Fig 6).
Fig 2. Interobserver analyses from small bowel. Scatter plots and Bland-Altman plots with limits of agreement depicting bias and error between
observer 1 and observer 2 for detection of small bowel transit time recorded with wireless motility capsule in healthy controls (2A,B) and in patients with
Familial GUCY2C Diarrhea Syndrome (2C,D).
https://doi.org/10.1371/journal.pone.0185496.g002
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“Snowglobes” were present in the jejunum in 18 of 21 FGDS patients and in 1 of 24 HC,
and in ileum in 20 of 21 FGDS patients and in 1 of 24 HC.
There were no significant differences between the antral areal in FGDS and HC before the
meal (p = 0.93) or in any of the postprandial (30, 60, 120 or 240 min) ultrasound measure-
ments (p = 0.65, p = 0.33, p = 0.80, p = 0.64 respectively). The RI index in SMA showed no dif-
ferences between FGDS or HC group before (p = 0.7) or after a meal (p = 0.72, p = 0.74,
p = 0.64, p = 0. 22, respectively).
Hormones
Blood samples from one of the HC was taken by a 20G cannula and the 5-HT measurement
from this subject was excluded because smaller needle size probably will affect the result by
Fig 3. Gastrointestinal pH measurements. Box plots showing the elevated pH values in the duodenum, small bowel and colon found in patients with
Familial GUCY2C diarrhea syndrome (FGDS) compared to healthy controls (HC). There was no difference in the stomach and antrum. The median is shown
within the box; the box represents the 25 and 75 percentiles and the whiskers 10 and 90 percentiles.
https://doi.org/10.1371/journal.pone.0185496.g003
Table 2. Pressures obtained by Wireless Motility Capsule (WMC). Intraluminal pressure parameters in mmHg, median and range obtained with WMC.
Colon data from 23 healthy controls and 14 patients are displayed.
Intraluminal Pressure in mmHg
Healthy controls FGDS patients
Segments Median Range Median Range p value
Stomach 2.3 1.4–3.4 2.0 1.4–3.4 0.41
Antrum 2.6 1.4–6.8 2.6 1.1–4.6 0.33
Duodenum 3.1 2.0–5.6 2.4 1.6–3.6 0.01
Small Bowel 3.6 3.0–7.2 2.8 1.8–5.8 0.02
Colon 3.9 2.2–6.1 2.7 2.1–4.3 0.002
https://doi.org/10.1371/journal.pone.0185496.t002
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giving elevated 5-HT levels. In addition, hormone analyzes of two FGDS patients were missing
due to technical problems with blood sampling.
Fig 7 illustrates the fasting and postprandial plasma hormone levels for all analyzed hor-
mones in FGDS patients and HC in a time course. ProGN levels were significantly lower in
FGDS patients compared with HC at baseline (p = 0.002) and all at postprandial timepoints
(p<0.05), whereas 5-HT levels were significantly higher in HC 30 minutes after the meal com-
pared to FGDS patients (p = 0.01).
There were no significant difference between FGDS patients and HC in plasma levels of
ProUGN, GLP-1 and PYY.
Correlations
Stool concistency (for both groups). There was a weak correlation between stool consis-
tency measured by BSC and CTT (r = 0.39, p = 0.02), and SBCTT (r = 0.5, p = 0.001), and
WGTT (r = 0.47, p = 0.01), but no correlation between BSC and SBTT (r = 0,28, p = 0.2). A
weak negative correlation between BSC and ProGN was seen (baseline; r = - 0.53, p< 0.001).
None of the other hormones tested, 5-HT, ProUGN, GLP-1 or PYY showed correlation to
stool consistency.
Stool frequency (only obtained in FGDS patients). There were no correlations between
the number of loose stools with any transit time measurements in the FGDS patients. Neither
did the number of stools correlate with the level of any gastrointestinal hormones.
Contractions, pressure and transit time (for both groups) obtained by WMC. Correla-
tion between colonic pressure and contractions (r = 0.667, p< 0.001), and between small
bowel pressure and contractions was found (r = 0.919, p>0.001).
Fig 4. Number of contractions obtained by Wireless Motility capsule (WMC). Box plots showing number of contractions per min in stomach, antrum,
duodenum, small bowel and colon recorded by WMC. There was no significant difference between the two groups in stomach or antrum. In the duodenum,
small bowel and in colon there was significant differences between FGDS and HC. The median is shown within the box; the box represents the 25 and 75
percentiles and the whiskers 10 and 90 percentiles.
https://doi.org/10.1371/journal.pone.0185496.g004
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A negative correlation, was found between CTT and colon contractions pr min (r = -0.509,
p = 0.001) and between CTT and colonic pressure (r = -0.37, p = 0.031). No correlation
between SBTT and contractions / pressure was found.
There were no correlations between number of loose stools/BSC and pressure /contractions
pr min in small bowel or colon.
Discussion
The main findings in this study are prolonged transit time through the gut, colon in particular,
and reduced luminal pressure in FGDS patients compared to a healthy control group matched
for age and gender. The number of contractions in duodenum, small bowel and colon recorded
with the WMC wasalso reduced in the FGDS patients. Interestingly,the FGDS patients have
increased number of non-occlusive contractions in small-bowel measured with ultrasound,
compared to HC. FGDS patients also have elevated pH in duodenum, small bowel and colon.
These findings support our previous results suggesting intestinal dysmotility in patients with
Fig 5. Contractions in small bowel obtained by Ultrasound. Box plots showing the number of non-occlusive ileal and jejunal contractions and the number
of occlusive ileal and jejunal contractions pr min obtained by ultrasound for each of the study time points. The median is shown within the box; the
box represents the 25 and 75 percentiles and the whiskers 10 and 90 percentiles. The black boxes display FGDS patients, the white boxes the Healthy
controls.
https://doi.org/10.1371/journal.pone.0185496.g005
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increased GC-C signaling [10]. There were few significant differences in gastrointestinal hor-
mones between FGDS patients and HC, but plasma levels of 5-HT in the FGDS patients did not
peak after the meal as observed in the HC.
CTT was almost twice as long in the FGDS patients compared to the HC(39.5 h in FGDS
patients versus 21.5 h in HC). Both were within normal range, but the difference between the
groups was significant. There are conflicting results regarding intestinal transit time both for
IBS patients with constipation and for those with diarrhea probably reflecting the many differ-
ent important regulatory factors affecting transit time and motility in the gut [11,28–30]. Pro-
longed CTT may be found in patients with slow transit constipation [31], but only a small
range of patients with IBS-C has slow transit time [32–34].
In accordance with other studies, we found that stool frequency correlated poorly with the
CTT [35,36]. Interestingly, we found a positive correlation between SBCTT, CTT, WGTT,
respectively and stool consistency according to the BSC. Although the correlation was weak,
these findings challenge the widely held notion that loose stools correlate with fast intestinal
transit [37–39]. In addition, there was a weak negative correlation between CTT, colon con-
tractions and colon pressure obtained by WMC. We also found a negative correlation between
BSC and plasma proGN which has not been described before. ProGN is secreted from the epi-
thelial cells both into the blood and intestinal lumen, and in conditions with loose stools it is
possible that secretion of proGN is reduced in order to maintain the fluid homeostasis.
The findings with regards to contractions measured by WMC and ultrasound may seem
contradictory. However, since the WMC only captures pressure inducing contractions it may
not register the non-occlusive contractions recorded with ultrasound. The pathogenic mecha-
nisms for the reduced and inefficient contractions in the FGDS patients are not clear, but it is
unlikely to be related to grossly disturbed levels of gastrointestinal hormones, as only plasma
ProGN was significantly lower in the FGDS patients compared to the HC at baseline and post-
prandial. Notably, the FGDS patients had no peak in plasma 5-HT secretion after the meal, as
we could observe in the HC. This suggests similarities to IBS-C patients where studies show no
peaks in plasma 5-HT after a meal [40]. 5-HT is an important neutrotransmitter in the gut, but
the excact mechanism is debatable, as some suggest that 5-HT secretion in the gut is a result of
peristalsis and not the cause of it [41,42].
Fig 6. Fluid- filled small bowel loops. The number of fluid-filled small bowel loops obtained by ultrasound.
There were significant differences between FGDS and HC for all measured points (p<0.001). Error bars are
shown as median with IQR (25 and 75 percentiles).
https://doi.org/10.1371/journal.pone.0185496.g006
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Fig 7. Gastrointestinal hormones. Median plots with IQR (25 and 75 percentiles) for the time course secretion of the different
hormones before (baseline) and after a meal. Significant differences were found between FGDS and HC regarding plasma
Proguanylin at all time points (baseline, 30 min, 60 min, 120 min and 240 min) and for plasma Serotonin 30 min postprandial (* p<
Prolonged intestinal transit and diarrhea in patients with an activating GUCY2C mutation
PLOS ONE | https://doi.org/10.1371/journal.pone.0185496 September 28, 2017 13 / 18
The increased formation of cellular cGMP caused by activation of GC-C [2,9] could possi-
bly influence smooth muscle contractions. cGMP is also transported out of the intestinal epi-
thelial cell where it has been shown to affect sensory afferent nerves [43–46]. This may explain
the lack of pain on daily basis observed in FGDS patients [2]. However the extracellular cGMP
may have other effects as well. In the intestine the intracellular nitric oxygene/soluble Guany-
late Cyclase pathway (NO/sGC) is important for the smooth muscle relaxation [47]. It has
been shown in mice that extracellular cGMP can affect this pathway in cerebellar tissue [48]. If
a similar effect occurs in the smooth muscle cells in the small bowel, this may cause a relaxing
effect in intestinal smooth muscles which in turn could lead to dysmotility and ineffective con-
tractions. This hypothesis needs to be addressed in future more mechanistic studies.
While the intestinal luminal pH is highly influenced by small chain fatty acids and other
metabolites produced by the intestinal microbiota which in turn are dependent on the nutri-
tion [49], our study demonstrates the influence on human intestinal pH by GC-C activation.
The luminal content is more alkaline in FGDS patients compared to HC from duodenum and
throughout the intestine. This is in accordance with the known effects of GC-C activation,
facilitating secretion of bicarbonate and impeding sodium and proton exchange across the
intestinal epithelium. Thus, increased intestinal pH is likely a primary effect of GC-C activa-
tion particularly in the smaller intestine which contains few bacteria, and is likely the reason
why a drop in pH between the small intestine and the cecum was absent in 6 of the FGDS
patients. However, FGDS patients have been shown to harbour a particular intestinal micro-
biota profile (Tronstad et al, in press) and this may additionally influence the pH in the colon.
Wang et al (2015) found by comparing a Swedish and American population, that the Swedes
exhibited lower pH in the gut generally and a longer SBTT and shorter CTT [50]. These find-
ings may reflect differences in nutrition composition which may lead to differences in the
microbiome, thus affecting the metabolism, fermentation and finally gut motility and transit
time. An increase in the luminal pH of the intestine caused by GC-C activation might override
the effect of bacterial metabolites on luminal pH and may play a role of the increased transit
time observed in FGDS patients.
A limitation of this study is that we did not observe the typical pH drop from small bowel
to colon in 6 of the FGDS patients and the transition was determined by the pressure waves
and pH pattern (Fig 1). However, the interobserver analyses showed high limits of agreement,
indicating that the recordings throughout the intestinal transit gave reliable results. Another
limitation of this study is the length of the videos acquired during ultrasound examinations (1
min videos) which may not fully represent the spectrum of all small bowel movements. How-
ever, the patients were all examined for altogether 4 hrs. Also, all subjects had an overnight fast
and received the same meal suggesting that they all were in similar motility states at least for
the time points registered after the meal.
Conclusion
In this study of patients with the monogenic disorder FGDS, we have for the first time demon-
strated that increased GC-C signaling leads to prolonged CTT and changes in intestinal motil-
ity coupled to measurements of intestinal pH and circulating intestinal hormones. The lack of
a plasma peak in 5-HT after a meal and prolonged colon transit time in the FGDS patients sug-
gest motility disturbances similar to patients suffering from constipation.
0.05,**p < 0.01). There were no significant differences in plasma measurements of GLP-1, PYY and Proguanylin between FGDS
and HC.
https://doi.org/10.1371/journal.pone.0185496.g007
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